CD274 and cancer: To the best of our knowledge, the present study, which combined short-term radiotherapy and PD-L1 expression status, is the first to evaluate retrospective data on patients with advanced ESCC cancer who received sintilimab and prior radiotherapy and were divided into two subgroups for comparison based on the time interval between radiotherapy and immunotherapy.